eNavvi Insights An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica Regulatory Status of Peptide Compounding in 2025 Frier Levitt Emerging And Approved Therapeutic Peptides: Mechanisms, Clinical Uses GlobalRPH The challenge for Minnesota wellness clinics in 2026 is navigating the shifting regulatory status of bioactive chains like BPC 157 or Ipamorelin. In Minnesota, peptides are legal only when prescribed In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few